Engineering ‘cell robots’ for parallel and highly sensitive screening of biomolecules under *in vivo* conditions

Lifu Song & An-Ping Zeng

Cells are capable of rapid replication and performing tasks adaptively and ultra-sensitively and can be considered as cheap “biological-robots”. Here we propose to engineer cells for screening biomolecules in parallel and with high sensitivity. Specifically, we place the biomolecule variants (library) on the bacterial phage M13. We then design cells to screen the library based on cell-phage interactions mediated by a specific intracellular signal change caused by the biomolecule of interest. For proof of concept, we used intracellular lysine concentration in *E. coli* as a signal to successfully screen variants of functional aspartate kinase III (AK-III) under *in vivo* conditions, a key enzyme in L-lysine biosynthesis which is strictly inhibited by L-lysine. Comparative studies with flow cytometry method failed to distinguish the wild-type from lysine resistance variants of AK-III, confirming a higher sensitivity of the method. It opens up a new and effective way of *in vivo* high-throughput screening for functional molecules and can be easily implemented at low costs.

High-throughput screening (HTS) technologies are powerful tools with many successful applications, especially in directed evolution of biomolecules such as enzymes. They are primarily based on chemical or physical readouts such as fluorescence and assisted with miniaturized and/or parallel devices such as microfluidics and microchip, increasingly in an automated manner with the help of robotics1–4. These systems require expensive infrastructure and special expertise. The major focus was put on speeding up the screening process. For example, the state-of-the-art HTS technology based on fluorescence activated cell sorting (FACS) can reach 18,000–20,000 events per second5. However, signal detection with fast moving cells is a challenge which can result in noisy signals as shown by previous studies6–9. Furthermore, single cell variations are another source of signal noise which cannot be avoided by FACS based methods10. These represent some of the shortcomings of presently used HTS technologies when the molecules to be evolved and optimized are to be used for regulation and improvement of metabolic pathways in the context of metabolic engineering or for creating new synthetic pathways and regulation tools.

Similar to the electric robots, microbial cells can be considered as a kind of “biological robots” that can sense the information of fast changing environment, compute and make decisions for survival. Cells are highly programmable as proved by recent developments in synthetic biology. Programming cells to perform specific tasks have been achieved successfully in many cases. For example, cells have been programmed to produce pharmaceuticals, fuels, amino acids, fine and bulk chemicals and even metal nanoparticles11–18. Cells also have been programmed to sense toxic compounds in environments19, to record the environment signal in human gut20 and to eradicate human pathogen21. Although the capability of a single cell is limited, cells can reproduce themselves exponentially and work simultaneously to solve complicated tasks or accomplish sophisticated tasks in principle. However, these capabilities of cells have not yet been well exploited, especially for HTS purpose.

Recently, concentrations of intracellular molecules have been used as signals for overexpression of fluorescence for screening purposes in the context of strain improvement4. For example, Binder *et al.* successfully used the intracellular concentration of lysine, a natural lysine-responsive transcriptional activator LysG and fused...
expression of eYFP to screen high lysine producer from *C. glutamicum*. Later, by using the same sensor for *in vivo* detection of the desired end-product in single cells, they established a screening method with FACS to screen for enzymes without allosteric inhibition. However, due to the complexity of metabolic pathways, one enhanced enzyme usually has limited effects on productivity of the end-product. Genetic modifications are required to enhance the signal of the end-product in their studies. Esvelt et al. (2011) presented an interesting phage-assisted method for continuous evolution of a specific gene-coded biomolecule that is linked to the infectivity of the phage mediated by the expression of a specific protein in host cells. Specifically, M13 filamentous bacteriophage carrying the molecule of interest was used to infect *E. coli* cells in a lagoon with continuous inflow and outflow of the host cells, where the evolving gene is transferred from host cell to host cell in a manner that is dependent on the activity of the molecule of interest. The method was demonstrated with the evolution of a T7 RNA polymerase for new binding properties. It was later on used to successfully evolve proteases with significantly increased drug resistance to protease inhibitor.

Here, we propose to use the cell-phage interactions mediated by the intracellular concentration of a specific metabolite for parallel and highly sensitive screening of biomolecules for metabolic pathway optimization under *in vivo* conditions. The basic idea is to program the cells to perform a certain screening task which is linked to the desired property or activity of the molecule of interest. The latter is in turn linked to the infectivity of the phage. Compared to physical robots the biological robots have the decisive advantage of fast replication, resulting in a large pool for simultaneously screening under *in vivo* conditions. Thus, the screening throughput can be expanded simply by using a larger population of cells, indicating a massively parallel screening manner potentially far beyond the current HTS technologies. It is also worth to mention that the cost for such an approach is almost zero compared to methods based on expensive FACS or microcapillary arrays, making it applicable in almost all biological labs.

We demonstrated the concept by screening mutants of a protein with reduced allosteric inhibition. Allosteric regulation is one of the fundamental mechanisms that control almost all cellular metabolism and gene regulation. Deregulation of allosteric inhibition is essential in designing and optimizing metabolic pathways for the production of target metabolites such as amino acids. Aspartate kinase III (AK-III), encoded by *lysC*, catalyzes the phosphorylation of aspartate and controls the biosynthesis of several industrially important amino acids such as lysine, threonine, and methionine in *E. coli*. AK-III is allosterically inhibited by L-lysine strictly. AK-III was chosen in this work as a model enzyme because of our extensive previous work on the rational design of it. The new approach is shown to be more sensitive than the widely used flow cytometry method owing to a novel way of signal capturing.

**Results**

**Principle of programming cells as robots for screening.** The workflow of programming cells as robots for the screening of molecule of interest (target) is shown in Fig. 1. Briefly, instead of placing the screening targets inside of the host cells as in most of the traditional screening methods, we place the targets to be screened on M13 phages. We then engineer the host cells so that they can screen for phages carrying the targets with desired properties. Specifically, we use *E. coli* XL1-Blue cells as the host cells for this purpose. To enable the host cells to control the infectivity of packaged phages, we transfer an essential gene for phage infectivity from the M13 phage to the host cells. The essential gene applied in this study is gene III encoding the attachment protein pIII which...
mediates adsorption of the phage to its primary receptor, the tip of *E. coli* F-pilus. We then design an intracellular biological circuit to control the infectivity of packaged phages by controlling the expression level of gene III based on a specific intracellular signal that is related to the performance of the biomolecules to be screened, such as the concentration of an end product or an intermediate metabolite of a metabolic pathway. The targets are then cloned into VCSM13 by replacing the original gene III. A helper plasmid pJ175-Str which can supply the gene III product is used for preparing infective phage library at the first step of screening (see below). Elimination of gene III does not affect the phage secretion. However, the infectivity of the produced phages is very low. Thus, to enable an effective screening, we design a two-step strategy as illustrated in Fig. 1. In the first step, the phage library with the variants is 'absorbed' and 'scored' by the host cells based on the strength of the specific signal representing the performance of the target molecule. High-performance targets will produce more infectious phages than the low-performance ones. In the second step, the 'scored' phages are collected and screened in another run of cell–phage interaction. In this step, only infectious phages carrying the molecule with desired property can be 'absorbed'. Since a kanamycin resistance gene (aph) is placed on the M13 phage, the cells capturing phages with desired properties can be selected easily by incubation under antibiotic pressure. In such a way, the target with the best performance under *in vivo* conditions can be effectively identified.

**Proof of concept of the method.** To use intracellular lysine concentration as a signal for the screening of an L-lysine-resistant aspartate kinase (AK-III, encoded by *lysC* gene in *E. coli*) based on the cell–phage interaction, a lysine inducible promoter was cloned from *Corynebacterium glutamicum* ATCC13032 as the lysine sensor. The gene III from M13 phage and a green fluorescence protein (GFP) encoding gene were placed under the control of the lysine inducible promoter. The GFP-encoding gene was used for comparing the sensitivity of the cell–phage based screening with the flow cytometry-based screening. It is not required for the cell robot based screening. (b) Biosynthesis pathway of lysine in *E. coli*. Green rectangles represent metabolites, light blue and yellow rectangles the names of related genes. In principle, the engineered host cells can be used to screen any enzymes in the lysine biosynthesis pathway for enhanced enzyme performance. In the proof of concept study, we focused on screening mutants of AK-III (encoded by the *lysC* gene) with reduced allosteric inhibition by lysine. PEP – phosphoenolpyruvate; AspP – L-aspartyl-4-phosphate; DPC – Tetrahydrodipicolinate; DL-DAP – D,L-diaminopimelate.

![Figure 2. Illustration of designed “cell robots” screening for targets which can increase intracellular lysine concentration.](image-url)
M13-lysC-V339A should be screened out. We repeated the experiments three times with the designed host cells using lysine as signals for screening. One time we used cells cultivated with LB medium and twice with cells cultivated with M9 medium, representing differential expression levels of lysine synthesis pathway genes under various conditions. To verify the genotypes of the resulting phages, plasmids extracted from six individual colonies were sequenced for each experiment. All colonies were verified to be M13-lysC-V339A in all three experiments, confirming a robust screening function of the designed “cell robots”.

In a further experiment, we screened a variant pool containing the wild-type AK-III, six AK-III mutants from previous study and a new mutant (R300C) obtained from screening a relatively small size of library with the present method (data not shown). In the first run of screening, we selected 12 colonies for sequencing which gave the following results: 5 for the variant V339A, 3 for the variant I337P, 2 for the variant S338L, and 1 for each of the variant T253R and H320A. In the second run using the phage mix from the 1st screening, we obtained only one colony of V339A. As shown in Fig. 3, the variant V339A has the highest activity and resistance against lysine, confirming the effectiveness of the two-step approach.

**Screening with a higher sensitivity than fluorescence-based method.** To compare the sensitivity of the current screening system with methods based on fluorescence and flow cytometry, the state-of-the-art screening technology, we transformed *E. coli* XL1-Blue/AP-Lys-B cells with M13-lysC, M13-lysC-V339A, and M13-lysC-R300C individually to obtain cells of XL1-Blue/AP-Lys-B/M13-lysC-WT, XL1-Blue/AP-Lys-B/M13-lysC-V339A, and XL1-Blue/AP-Lys-B/M13-lysC-R300C. A GFP-encoding gene was placed under the control of the same lysine sensing sensor in *E. coli* XL1-Blue/AP-Lys-B. Over-night cultivated cells of XL1-Blue/AP-Lys-B, XL1-Blue/AP-Lys-B/M13-lysC-WT, XL1-Blue/AP-Lys-B/M13-lysC-V339A and XL1-Blue/AP-Lys-B/M13-lysC-R300C were harvested and washed twice with 50 mM, ice-cooled PBS buffer. The fluorescence activities of the four different cell populations were measured using flow cytometry. As shown in Fig. 4b, although slight differences could be observed, it was not possible to set up a gain setting to select the mutants. In other words, the different cell populations cannot be distinguished by the flow cytometry method. On the other hand, our method based on cell-phage interaction can successfully screen out V339A as the best mutant of AK-III as shown in Fig. 3, confirming a higher sensitivity of the cell robot based screening method.

Biological systems are complex and highly adaptive, meaning that the cells always try to reduce the perturbations introduced. Introducing molecular variants into cells can be regarded as perturbations to the cells. As illustrated in Fig. 4c, after the introduction of molecular variants, the cells may undergo three stages of signal change: enhancement, attenuation and stabilization. The signal enhancement stage is the direct consequence of the perturbations induced by the introduced molecular variants. The signal attenuation stage is caused by adaptive response of cells to the perturbation. Finally, the signal reaches a stable state which might be slightly different from the state before the perturbation. The time interval for these changes may be relatively short. The curves in Fig. 4c are theoretical response patterns of cells to the disturbance by over-expression of the different AK-III variants respectively. For the FACS based method, the cells to be measured may have already reached the stable stage where the signal strength may not be significantly different in the cell populations with different variants. However, our method captures signals during the whole response and adaptation processes which correspond to the area below the curves and can be therefore more sensitive.

Furthermore, the “cell robots” based screening works in principle like an autocatalytic process of signal amplification: the target molecule with desired performance will increase the intracellular concentration of the signal.
molecule (in this case lysine) in the cell, the increased concentration of the signal molecule will amplify the population of phage carrying the target molecule. The amplified phages can infect other cells to further enhance the signal. In such a way the screening process is highly effective and sensitive compared to the other presently used methods, such as those based on single cells using fluorescence as readout signal.

Discussion

In this study, we demonstrated that the biological ‘robots’, i.e. the cells, can be engineered to perform screening tasks in protein engineering. By capturing the signals during the whole response and adaptation processes, which cannot be achieved by screening based on electric machines, the cell-phage based screening system has an inherent higher sensitivity. The current proof of concept study shows that cell-phage interaction system does not require any genetic modifications of the host cells to enhance the signal. In such a way the screening process is highly effective and sensitive compared to the other presently used methods, such as those based on single cells using fluorescence as readout signal.

Figure 4. Flow Cytometry assays of cell populations harboring wild-type AK-III and AK-III muteins. (a) Dot plot of flow cytometry assay results. (b) Statistic analysis of the total cell numbers at different fluorescence intensities. (c) Illustration of differences in signal capture of the cell-robot based and the FACS-based screening methods. Phagemids M13-lysC, M13-lysC-V339A and M13-lysC-R300C were transformed to E. coli XL1-Blue/AP-Lys-B cells individually. Flow Cytometry assays were performed on the obtained cell populations by measuring green fluorescence intensity. Although slight differences could be observed in figure (b), the flow cytometry method failed to distinguish the mutants despite varying the gain setting. Introduction of molecular variants into cells can be regarded as perturbations to the cells. Figure (c) illustrates possible change of signal after introduction of variants (perturbations): enhancement, attenuation and stabilization.

molecule (in this case lysine) in the cell, the increased concentration of the signal molecule will amplify the population of phage carrying the target molecule. The amplified phages can infect other cells to further enhance the signal. In such a way the screening process is highly effective and sensitive compared to the other presently used methods, such as those based on single cells using fluorescence as readout signal.
in computational science, parallelization is a great solution for speeding up the process of parallel tasks. The sensitivity and throughput are key factors determining the success of a screening experiment. The cell-phage screening system shows clear advantages in both sensitivity and throughput. Furthermore, the cost of cell robots is almost zero compared to that of expensive electric machines/robots. It should be mentioned that, while electric machines can utilize various types of signals for screening, screening based on the cell robots uses a “biological signal and sensor”, which might represent a limitation in some cases. However, many natural or purposefully designed biological elements or sensors such as promoters and riboswitches can be used for this purpose and the signal molecules can be intermediates of metabolic pathways.

**Materials and Methods**

**Strains, phages and plasmids.** The M13 phage (VCSM13) was purchased from Agilent Technology (5301 Stevens Creek Blvd. Santa Clara, CA 95051, USA). The wild lysC gene encoding AK-III was amplified by PCR from the genomic DNA of *E. coli* K12 MG1655. For over-expression and purification of the wild-type AK-III and relevant muteins, the wild-type lysC gene was cloned to pET-22b (+) with the introduction of an additional His-tag at the C-terminal to generate the plasmid pET22-lysC. Site-mutagenesis was performed on pET22-lysC to generate over-expression plasmids for AK-III muteins. The lysC gene was also cloned to VCSM13 by replacing the original gene III to generate a phagemid M13-lysC. Similarly, site-mutagenesis was also performed on M13-lysC to generate phagemid derivations carrying different AK-III muteins.

For construction of plasmid AP-Lys-B, i.e. the device harnessed by the host cells to control the phage packaging process based on intracellular lysine concentration, we utilized a lysine inducible promoter from *Corynebacterium glutamicum* to generate phagemid derivations carrying different AK-III muteins. The *C. glutamicum* lysC gene was also cloned to VCSM13 by replacing the relevant muteins, the wild-type lysC (with the introduction of an additional His-tag at the C-terminal to generate the plasmid pET22-lysC. Site-mutagenesis was performed on pET22-lysC to generate the plasmid pET22-lysC. The transcriptional levels of gene III and GFP encoding gene are controlled by the lysine inducible promoter. The antibiotic resistance type of AP-Lys-B was changed to ampicillin resistance by replacing the kanamycin resistance gene with an ampicillin resistance gene. All used strains, plasmids in current study are listed in Table 1.

**Molecular cloning.** All PCR experiments for cloning were performed using Thermo Scientific PCR Master Mix or CloneAmp HiFi PCR Premix. Cloning experiments were performed using In-Fusion HD Cloning Plus. Site-mutagenesis was performed using a protocol similar to the NEB Q5® Site-Directed Mutagenesis Kit. Briefly, none overlap primers were designed and synthesized which contain the desired mutations. Then PCR amplification was performed with the designed primers using the original plasmid as templates to generate linear plasmids. Template DNA was eliminated by enzymatic digestion with DpnI. Finally, phosphorylation and ligation using T4 Polynucleotide Kinase and T4 Ligase were carried out to obtain circular DNA before transformation.

**Mutagenesis.** Random in vivo mutagenesis was enabled by using the plasmid pJ184-Str harboring genes which can increase intracellular DNA replication error rates. The plasmid pJ184-Str was derived from pJ184 by replacing the chloramphenicol acetyltransferase encoding gene with a streptomycin resistance gene. The pJ184 plasmid which has been described previously was obtained from David R. Liu’s group of Harvard Medical School.

**Preparation of infective phages for screening.** Since the engineered phages lack gene III, the helper plasmid pJ175e was harnessed by the host cells to supply gene III products intracellularly to obtain infective phages. The plasmid pJ175e was obtained from David R. Liu’s group. Specifically, engineered phages were co-transformed with pJ175e into XL1-Blue cells. Overnight cultures were deposited for centrifuge and the supernatant containing the packaged infective phages was collected.

**Screening based on cell robots.** XL1-Blue/AP-Lys-B cells, i.e. the “cell robots”, were incubated in LB medium to an OD600 value around 1.0. Roughly 200ul XL1-Blue/AP-Lys-B cells were mixed with 2ul proper diluted phages (Cells to phage number ratio above 10:1 to make sure that all phages could be captured and evaluated by host cells. Different types of phages in a total number of roughly 10,000 were used as inputs in the present study). The mixture was incubated at 37 °C for 15 minutes without shaking to allow the phages to attach to the cells, following by incubation at 37 °C with shaking for 1 to 2 hours. Inactivate the host cells at 65 °C for 15 min. The cell debris were spun down and the supernatant containing the “scored” phages was transferred to a fresh tube. A proper amount of “scored” phages were mixed with fresh XL1-Blue/AP-Lys-B cells and incubated at 37 °C for 15 minutes without shaking to allow the “cell robots” to absorb the highly “scored” phages. A proper amount of the culture was then sprayed on LB agar plates with kanamycin (50 mg/ml) for screening.

**Protein purification and enzyme activity assay.** Enzymes were expressed in *E. coli* BL21 (DE3) cells (New England Biolabs, Germany) using PET derived plasmids. The recombinant cells were first cultivated in LB media supplemented with 50 μg/mL kanamycin at 37 °C to reach an OD600 of 0.6 and then protein expression was induced by adding 0.1 mM isopropyl β-D-thiogalactopyranoside (IPTG) for overnight at 30 °C. The harvested cells were washed twice with 20 mM Tris–HCl buffer (pH 7.0) and suspended in a buffer of 50 mM Na2HPO4 (pH 7.0), 0.2 mM EDTA and 0.1 mM dithiothreitol. Suspended cells were disrupted and centrifuged at 100,000 g for 1 h. The crude enzymes, e.g. the supernatant, was purified using a Ni2+/-NTA column (GE Healthcare Bio-Sciences, Piscataway, NJ) to obtain samples for activity assay.

The aspartokinase activities of AK-III and muteins were assayed using the hydroxamate method. In details, 1 ml reaction mixture contained 200 mM Tris–HCl (pH 7.5), 10 mM MgSO4, 6H2O, 10 mM aspartate, 10 mM ATP, 160 mM NH4OH–HCl and appropriate amounts of enzyme. After incubation at 30 °C for 30 min, the reaction was stopped by mixing with 1 ml 5% (w/v) FeCl3 solution and the absorbance at 540 nm was monitored.
| Strains/phages/plasmids/primers | Description/Genotype | Note |
|---------------------------------|----------------------|------|
| **Strains**                     |                      |      |
| E. coli XL1-Blue                |                      |      |
| E. coli XL1-Blue/pJ175e         | E. coli XL1-Blue harboring pJ175e |      |
| E. coli XL1-Blue/AP-Lys-B        |                      |      |
| E. coli XL1-Blue/AP-Lys-B/M13-lysC | E. coli XL1-Blue harboring AP-Lys-B and M13-lysC |      |
| E. coli XL1-Blue/AP-Lys-B/M13-lysC-V339A | E. coli XL1-Blue harboring AP-Lys-B and M13-lysC-V339A |      |
| **Phages**                      |                      |      |
| VCSM13                          |                      |      |
| M13-lysC                        | Derived from VCSM13 by replacing gene III with wild lysC from E. coli K12 | Plasmid map and full sequence are detailed in Supplementary information. |
| M13-lysC-T253R                  | Derived from M13-lysC by site mutagenesis |      |
| M13-lysC-R300C                  | Obtained by screening with a library of M13-lysC generated by in vivo random mutagenesis |      |
| M13-lysC-R305A                  | Derived from M13-lysC by site mutagenesis |      |
| M13-lysC-H320A                  | Derived from M13-lysC by site mutagenesis |      |
| M13-lysC-I337P                  | Derived from M13-lysC by site mutagenesis |      |
| M13-lysC-S338L                  | Derived from M13-lysC by site mutagenesis |      |
| M13-lysC-V339A                  | Derived from M13-lysC by site mutagenesis |      |
| **Plasmids**                    |                      |      |
| pJ175e                          | Amp, obtained from David Group |      |
| AP-Lys-B                        | Amp, Derived from pZE21 plasmid; Plasmid map and full sequence are detailed in Supplementary information. |      |
| pET22-lysC                      | Amp, Expression plasmid for wild-type AK-III |      |
| pET22-lysC-T253R                | Expression plasmid for T253R mutant of AK-III |      |
| pET22-lysC-R300C                | Expression plasmid for R300C mutant of AK-III |      |
| pET22-lysC-R305A                | Expression plasmid for R305A mutant of AK-III |      |
| pET22-lysC-H320A                | Expression plasmid for H320A mutant of AK-III |      |
| pET22-lysC-I337P                | Expression plasmid for I337P mutant of AK-III |      |
| pET22-lysC-S338L                | Expression plasmid for S338L mutant of AK-III |      |
| pET22-lysC-V339A                | Expression plasmid for V339A mutant of AK-III |      |
| **Primers**                     |                      |      |
| M13seq-G3-P1                    | Sequencing primer    | TCTGTAGCCGTGCTACCCCTCGTT |
| M13seq-G3-P2                    | Sequencing primer    | AAGAAACATGAATAGCAATAA    |
| M13-ln4Genes-P1                 | Primer for linearization of VCSM13 | CTAGTATTTTCCTCCTCCTGGTTTTATCAGCTTGCT |
| M13-ln4Genes-P2                 | Primer for linearization of VCSM13 | CTCCCTCTAATGGTTTAGAAAG |
| LysC-4M13-P1                    | For cloning of lysC | GAGGAGAAATACTAGATGTCTGAAATGTGTGTTCCTC |
| LysC-4M13-P2                    | For cloning of lysC | AACCAGTTAGGGAGTACTCACCACAAATATTACCTG |
| V339A-P1                        | Site-directed mutagenesis of lysC to generate V339A mutant | GCAGACCTTAATCACCAGCTGAAAG |
| V339A-P2                        | Site-directed mutagenesis of lysC to generate V339A mutant | CGAAATTTATGCGCGCGGGAGG |
| T253R-P1                        | Site-directed mutagenesis of lysC to generate T253R mutant | CGTTTTTGTCGAAAAAGTTACTG |
| T253R-P2                        | Site-directed mutagenesis of lysC to generate T253R mutant | TGCCATCTCCGGGCTTCGAGC |
| R305A-P1                        | Site-directed mutagenesis of lysC to generate R305A mutant | TGCTGGAAATCAGACTCTGCT |
| R305A-P2                        | Site-directed mutagenesis of lysC to generate R305A mutant | AGGCCAGAGGGCCGAAAGC |
| H320A-P1                        | Site-directed mutagenesis of lysC to generate H320A mutant | TTTCGCGGTTIITCTCGCGGAA |
| H320A-P2                        | Site-directed mutagenesis of lysC to generate H320A mutant | GCCAGACATTTACGCGTGCG |
| I337P-P1                        | Site-directed mutagenesis of lysC to generate I337P mutant | CTTCGGTAAGACTTATACCAC |
| I337P-P2                        | Site-directed mutagenesis of lysC to generate I337P mutant | GATTATGGCGCGCGAGGATGG |
| S338L-P1                        | Site-directed mutagenesis of lysC to generate S338L mutant | TGGTGAATTTATACACCTAGTC |
| S338L-P2                        | Site-directed mutagenesis of lysC to generate S338L mutant | AAATATTATGCGCGCGGGAGG |
| R300C-P1                        | Site-directed mutagenesis of lysC to generate R300C mutant | TGCCGCTTCGGGCTTCGCGC |
| R300C-P2                        | Site-directed mutagenesis of lysC to generate R300C mutant | GAACACGGCGCGGATTTCAGGTTA |

**Table 1.** Strains, plasmids and primers used in this study.
Flow cytometry analysis. Overnight cultured cells were washed and re-suspended in ice-cooled 50 mM PBS buffer and diluted to a cell density of approximately $3 \times 10^6$ cells/mL. Then, cellular GFP was analyzed by using flow cytometry (Beckman Coulter CytoFlex) with excitation at 480 nm and detecting fluorescence at 529 ± 14 nm. For each sample, 50,000 events were recorded. Data were analyzed using the CytExpert software.

Data availability statement. All data are provided in full in the results section of this paper.

References

1. Bornscheuer, U. T. Protein engineering: Beating the odds. *Nature chemical biology* **12**, 54–55 (2016).
2. Chen, B. et al. High-throughput analysis and protein engineering using microcarpillary arrays. *Nature chemical biology* **12**, 76–81 (2016).
3. Colin, P.-Y. et al. Ultrahigh-throughput discovery of promiscuous enzymes by picodroplet functional metagenomics. *Nature communications* **6**, 10008 (2015).
4. Colin, P.-Y., Zanchenko, A. & Hollfelder, F. Enzyme engineering in biomimetic compartments. *Current opinion in structural biology* **33**, 42–51 (2015).
5. Aghaeepour, N. et al. Critical assessment of automated flow cytometry data analysis techniques. *Nature methods* **10**, 228–238 (2013).
6. Arnold, I. W. & Lannigan, J. Practical issues in high-speed cell sorting. *Current protocols in cytometry/editorial board, J. Paul Robinson, managing editor* et al. *Chapter 1, Unit 1.24, 1–30* (2010).
7. Binder, S. et al. A high-throughput approach to identify genomic variants of bacterial metabolite producers at the single-cell level. *Genome biology* **13**, R40 (2012).
8. Schendzielorz, G. et al. Taking control over control: use of product sensing in single cells to remove flux control at key enzymes in biosynthesis pathways. *ACS synthetic biology* **3**, 21–29 (2014).
9. Wang, Y. et al. Evolving the L-lysine high-producing strain of Escherichia coli using a newly developed high-throughput screening method. *Journal of industrial microbiology & biotechnology* (2016).
10. Young, J. W. et al. Measuring single-cell gene expression dynamics in bacteria using fluorescence time-lapse microscopy. *Nature protocols* **7**, 80–88 (2012).
11. Ahn, J. H., Jang, Y.-S. & Lee, S. Y. Production of succinic acid by metabolically engineered microorganisms. *Current opinion in biotechnology* **42**, 54–66 (2016).
12. Choi, S. Y. et al. One-step fermentative production of poly(lactate-co-glycolate) from carbohydrates in Escherichia coli. *Nature biotechnology* **34**, 435–440 (2016).
13. Park, T. J., Lee, K. G. & Lee, S. Y. Advances in microbial biosynthesis of metal nanoparticles. *Applied microbiology and biotechnology* **100**, 521–534 (2016).
14. Park, S. H. et al. Metabolic engineering of Corynebacterium glutamicum for L-arginine production. *Nature communications* **5**, 4618 (2014).
15. Liao, J. C., Mi, L., Pontrelli, S. & Luo, S. Fuelling the future: microbial engineering for the production of sustainable biofuels. *Nature reviews. Microbiology* **14**, 288–304 (2016).
16. Bomareddy, R. R., Chen, Z., Rappert, S. & Zeng, A.-P. A de novo NADPH generation pathway for improving lysine production of Corynebacterium glutamicum by rational design of the coenzyme specificity of glyceraldehyde 3-phosphate dehydrogenase. *Metabolic engineering* **25**, 30–37 (2014).
17. Lee, J. H., Mitchell, R. J., Kim, B. C., Cullen, D. C. & Gu, M. B. A cell array biosensor for environmental toxicity analysis. *Biosensors & bioelectronics* **21**, 500–507 (2005).
18. Kotula, J. W. et al. Programmable bacteria detect and record an environmental signal in the mammalian gut. *Proceedings of the National Academy of Sciences of the United States of America* **111**, 4838–4843 (2014).
19. Saeidi, N. et al. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. *Molecular systems biology* **7**, 521 (2011).
20. Esselt, K. M., Carlson, J. C. & Liu, D. R. A system for the continuous directed evolution of biomolecules. *Nature* **472**, 499–503 (2011).
21. Dickinson, B. C., Packe, M. S., Badran, A. H. & Liu, D. R. A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. *Nature communications* **5**, 5352 (2014).
22. Badran, A. H. et al. Continuous evolution of Bacillus thuringiensis toxins overcomes insect resistance. *Nature* **533**, 58–63 (2016).
23. Carlson, J. C., Badran, A. H., Guggiana-Nilo, D. A. & Liu, D. R. Negative selection and stringency modulation in phage-assisted continuous evolution. *Nature chemical biology* **10**, 216–222 (2014).
24. Tsai, C.-J., Del Sol, A. & Nussinov, R. Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. *Molecular bioSystems* **5**, 207–216 (2009).
25. Chen, Z., Rappert, S., Sun, J. & Zeng, A.-P. Integrating molecular dynamics and co-evolutionary analysis for reliable target prediction and deregulation of the allosteric inhibition of aspartokinase for amino acid production. *Journal of biotechnology* **154**, 248–254 (2011).
26. Theze, J., Margarita, D., Cohen, G. N., Borne, F. & Patte, J. C. Mapping of the structural genes of the three aspartokinases and of the two homoserine dehydrogenases of Escherichia coli K-12. *Journal of bacteriology* **117**, 133–143 (1974).
27. Black, S. & Wright, N. G. Beta-Aspartokinase and beta-aspartyl phosphate. *The Journal of biological chemistry* **213**, 27–38 (1955).
Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15621-0.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017